BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 27496633)

  • 1. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
    Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
    J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
    Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
    J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
    Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
    Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
    Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
    J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
    Wyatt EA; Davis ME
    Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.
    Mehta AI; Brufsky AM; Sampson JH
    Cancer Treat Rev; 2013 May; 39(3):261-9. PubMed ID: 22727691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
    Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
    Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
    Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
    Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.
    Russillo M; Ferretti G; Vidiri A; Gasparro S; Cognetti F; Pellegrini D; Fabi A
    In Vivo; 2018; 32(4):839-842. PubMed ID: 29936468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
    Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
    Teplinsky E; Esteva FJ
    Curr Oncol Rep; 2015 Oct; 17(10):46. PubMed ID: 26314739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
    Eiger D; Pondé NF; de Azambuja E
    Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
    Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
    Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.
    O'Reilly MA; Chinnery T; Yee ML; Wu SK; Hynynen K; Kerbel RS; Czarnota GJ; Pritchard KI; Sahgal A
    Sci Rep; 2018 Jun; 8(1):9013. PubMed ID: 29899537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
    Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
    Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
    Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
    Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
    Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.
    Kinoshita M; McDannold N; Jolesz FA; Hynynen K
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11719-23. PubMed ID: 16868082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.